Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 9,970 Shares

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 9,970 shares of the firm’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $25.48, for a total transaction of $254,035.60. Following the transaction, the director now directly owns 1,262,759 shares of the company’s stock, valued at approximately $32,175,099.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Gregory Bailey also recently made the following trade(s):

  • On Friday, November 24th, Gregory Bailey sold 600 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $26.02, for a total transaction of $15,612.00.
  • On Monday, November 27th, Gregory Bailey sold 20,600 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $25.92, for a total transaction of $533,952.00.

Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) traded down $0.55 during midday trading on Friday, reaching $22.58. 579,393 shares of the company were exchanged, compared to its average volume of 211,629. Biohaven Pharmaceutical Holding Co Ltd has a fifty-two week low of $17.00 and a fifty-two week high of $39.51.

Several equities analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. BidaskClub raised shares of Biohaven Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price target (up previously from $30.00) on shares of Biohaven Pharmaceutical in a research note on Wednesday, September 13th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $54.00 price target on shares of Biohaven Pharmaceutical in a research note on Tuesday, September 12th. Finally, Morgan Stanley raised their price target on shares of Biohaven Pharmaceutical from $28.00 to $47.00 and gave the company an “overweight” rating in a research note on Monday, September 25th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Biohaven Pharmaceutical currently has an average rating of “Buy” and an average target price of $40.80.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc bought a new position in Biohaven Pharmaceutical during the third quarter worth $119,000. Nationwide Fund Advisors acquired a new stake in Biohaven Pharmaceutical in the third quarter worth $214,000. American International Group Inc. acquired a new stake in Biohaven Pharmaceutical in the third quarter worth $251,000. State of Wisconsin Investment Board acquired a new stake in Biohaven Pharmaceutical in the third quarter worth $262,000. Finally, Susquehanna International Group LLP acquired a new stake in Biohaven Pharmaceutical in the third quarter worth $302,000. 47.76% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Gregory Bailey Sells 9,970 Shares” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/01/biohaven-pharmaceutical-holding-co-ltd-bhvn-director-gregory-bailey-sells-9970-shares.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply